JANX Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -82.06%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Janux Therapeutics, Inc. has a consensus price target of $63.59, signalling upside risk potential of 320%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.63 which suggests that it could grow by 10.8%. Given that Janux Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 91.81x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 31.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Eli Lilly & Co.'s return on equity of 106.26%.

Janux Therapeutics, Inc. has a consensus price target of $63.59, signalling upside risk potential of 320%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.72 which suggests that it could grow by 2.15%. Given that Janux Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Janux Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.55% to investors and pays a quarterly dividend of $1.50 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 91.81x versus 16.68x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -39.75%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Janux Therapeutics, Inc. has a consensus price target of $63.59, signalling upside risk potential of 320%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $635.21 which suggests that it could grow by 27.54%. Given that Janux Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.001, suggesting its less volatile than the S&P 500 by 200.123%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 91.81x versus 14.91x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 9.72%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat MannKind Corp.'s return on equity of --.

Janux Therapeutics, Inc. has a consensus price target of $63.59, signalling upside risk potential of 320%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.63%. Given that Janux Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Janux Therapeutics, Inc. is more attractive than MannKind Corp..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than MannKind Corp.'s net income of $8M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 62.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 91.81x versus 5.81x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.